Literature DB >> 24474889

Validation of Serological Testing for Anti-Treponema pallidum from Postmortem Blood on the Siemens-BEP(®)-III Automatic System.

Ulrich Kalus1, Ina Wilkemeyer1, Axel Pruss1, Gregor Caspari2.   

Abstract

BACKGROUND: Infectious disease marker testing is obligatory for the release of human tissue for transplantation. Most CE-marked tests are not validated for postmortem blood. In a previous study we have validated the testing for anti-HIV-1/2, anti-HCV, HBsAg, and anti-HBc. Here, we present the validation of testing for antibodies against T. pallidum, which is the last marker obligatory for tissue release for transplantation.
METHODS: 17 samples of postmortem sera and 10 samples of both pre-und postmortem sera were obtained from cornea donors and tested for anti-T. pallidum on the Siemens-BEP-III-System. These sera were spiked with anti-T. pallidum-positive standard sera in concentrations which give low- and high-positive results at the respective dilution.
RESULTS: Two of the unspiked postmortem sera were false-positive most likely due to intense hemolysis (free hemoglobin > 50 mg/dl). Of the 25 negative postmortem sera, none of the spiked samples was false-negative after 0, 24 and 60 h.
CONCLUSION: There is no indication that postmortem samples give false-negative or false-positive results with the test system and test kits used in cases of low hemolysis. The procedure described might serve as a model for validating other test kits on postmortem samples.

Entities:  

Keywords:  Blood testing; Infectious disease serology; Postmortem blood; Tissue donation; Treponema pallidum

Year:  2013        PMID: 24474889      PMCID: PMC3901593          DOI: 10.1159/000354070

Source DB:  PubMed          Journal:  Transfus Med Hemother        ISSN: 1660-3796            Impact factor:   3.747


  7 in total

1.  Validation of the Serological Testing for Anti-HIV-1/2, Anti-HCV, HBsAg, and Anti-HBc from Post-mortem Blood on the Siemens-BEP-III Automatic System.

Authors:  Ulrich Kalus; Ina Wilkemeyer; Gregor Caspari; Jan Schroeter; Axel Pruss
Journal:  Transfus Med Hemother       Date:  2011-11-17       Impact factor: 3.747

Review 2.  Syphilis and blood transfusion: a global perspective.

Authors:  A De Schryver; A Meheus
Journal:  Transfusion       Date:  1990 Nov-Dec       Impact factor: 3.157

3.  Serodiagnosis of syphilis in the recombinant era: reversal of fortune.

Authors:  Karen W Hoover; Justin D Radolf
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

Review 4.  [Current aspects in the diagnosis of syphilis].

Authors:  H J Hagedorn
Journal:  Immun Infekt       Date:  1993-08

5.  The stability of hepatitis C virus RNA after storage at +4 degrees C.

Authors:  G Gessoni; P Barin; A Frigato; M Fezzi; G de Fusco; N Arreghini; P Galli; G Marchiori
Journal:  J Viral Hepat       Date:  2000-07       Impact factor: 3.728

6.  A prospective time-course study on serological testing for human immunodeficiency virus, hepatitis B virus and hepatitis C virus with blood samples taken up to 48 h after death.

Authors:  Carolin Edler; Birgit Wulff; Ann-Sophie Schröder; Ina Wilkemeyer; Susanne Polywka; Thomas Meyer; Ulrich Kalus; Axel Pruss
Journal:  J Med Microbiol       Date:  2011-03-24       Impact factor: 2.472

7.  Comparison of the efficacy of virus inactivation methods in allogeneic avital bone tissue transplants.

Authors:  A Pruss; A Hansen; M Kao; L Gürtler; G Pauli; F Benedix; R Von Versen
Journal:  Cell Tissue Bank       Date:  2001       Impact factor: 1.522

  7 in total
  2 in total

1.  Advanced therapy medicinal products - a multiple challenge.

Authors:  Axel Pruss; Henk Garritsen
Journal:  Transfus Med Hemother       Date:  2013-12       Impact factor: 3.747

2.  Validation of Spiked Postmortem Blood Samples from Cornea Donors on the Abbott ARCHITECT and m2000 Systems for Viral Infections.

Authors:  Ingo Schmack; Seda Ballikaya; Brigitte Erber; Irina Voehringer; Ulrich Burkhardt; Gerd U Auffarth; Paul Schnitzler
Journal:  Transfus Med Hemother       Date:  2019-09-24       Impact factor: 3.747

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.